Whilst not a systematic review, this article aims to provide an insight into the current anti-HER2 therapies and discuss the optimal sequencing in order to maximise the benefit of treatment and control of metastatic disease burden for patients with HER2-positive ABC. This evidence concerns the gene ERBB2 and metastatic neoplasm.